LATS1 Antibody [A5C10]

Application: Reactivity: Human, Mouse, Monkey

Usage Information

Dilution
WB1:1000 IP1:100

Application
WB, IP

Reactivity
Human, Mouse, Monkey

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
140 kDa

Datasheet & SDS

Biological Description

Specificity
LATS1 Antibody [A5C10] detects endogenous levels of total LATS1 protein.

Clone
A5C10

Synonym(s)
Hippo

Background
LATS1 (Large Tumor Suppressor Kinase 1) is a serine/threonine kinase of the AGC family and a core component of the Hippo signaling pathway. Structurally, it contains an N-terminal regulatory domain (NTR), a catalytic kinase domain with a unique insert between subdomains VII and VIII, and two conserved phosphorylation sites: the activation segment (AS; Ser909) and hydrophobic motif (HM; Thr1079), essential for its activity. LATS1 is widely expressed in mammalian tissues, where it acts as a tumor suppressor by phosphorylating YAP/TAZ to inhibit their nuclear localization and transcriptional co-activation, thereby regulating cell proliferation, apoptosis, and differentiation. Its regulation involves multiple phosphorylation events by upstream kinases (MST1/2, MAP4Ks, CDK1/cyclin B, NUAK1), adaptor proteins (MOB1, SAV1, angiomotins), and control of protein stability by HSP90, ROS-PKCδ signaling, and ubiquitin ligases, highlighting its central role in maintaining tissue homeostasis and preventing tumorigenesis.

Background

LATS1 (Large Tumor Suppressor Kinase 1) is a serine/threonine kinase of the AGC family and a core component of the Hippo signaling pathway. Structurally, it contains an N-terminal regulatory domain (NTR), a catalytic kinase domain with a unique insert between subdomains VII and VIII, and two conserved phosphorylation sites: the activation segment (AS; Ser909) and hydrophobic motif (HM; Thr1079), essential for its activity. LATS1 is widely expressed in mammalian tissues, where it acts as a tumor suppressor by phosphorylating YAP/TAZ to inhibit their nuclear localization and transcriptional co-activation, thereby regulating cell proliferation, apoptosis, and differentiation. Its regulation involves multiple phosphorylation events by upstream kinases (MST1/2, MAP4Ks, CDK1/cyclin B, NUAK1), adaptor proteins (MOB1, SAV1, angiomotins), and control of protein stability by HSP90, ROS-PKCδ signaling, and ubiquitin ligases, highlighting its central role in maintaining tissue homeostasis and preventing tumorigenesis.

References
https://pubmed.ncbi.nlm.nih.gov/23985307/ https://pubmed.ncbi.nlm.nih.gov/30266805/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%

Home Primary Antibodies LATS1 Antibody [A5C10]

Usage Information

Datasheet & SDS

Biological Description

Tech Support